Some comparisons exist to declare a winner; this one exists to kill a confusion, because iatroX and emc solve adjacent problems and the prescriber who understands the adjacency uses both better. emc is the source of record: more than 14,000 regulated medicines documents, SmPCs and PILs checked and approved by the MHRA or EMA, organised by exact medicinal product, with companies expected to update within ten days of an approved change. iatroX is a front door: Ask-iatroX starts from the clinical question and retrieves UK guidance, relevant SmPCs on emc and peer-reviewed research with direct links, while the Medicines pages organise selected UK products with review dates and the source trail intact. One is where authorised product information lives; the other is how you find which documents your question actually needs, and the brand message this platform stands behind is exactly that shape: iatroX does not replace emc, it makes it easier to know when and where to use it.
Three test questions that reveal the division
"What should I consider when initiating this medicine?" A cross-source question, pathway placement, patient factors, monitoring, counselling, product cautions, and the front door leads: an Ask-iatroX response assembles the guideline position, the relevant product information and the research context with links, which no single emc document was built to do. "Is this particular formulation licensed for this patient?" A product question, and the source of record decides: the exact SmPC for the exact brand, strength and formulation is the regulatory answer, and any synthesis, ours included, is a pointer to it rather than a substitute for it, because licensing lives at product level and generic summaries blur exactly the distinctions that matter. "How does this medicine fit within the current treatment pathway?" A guidance question routed through the front door to NICE, CKS or SIGN, where the SmPC is silent by design, an authorisation document has no opinion on what should be tried first. Notice the pattern across all three: the front door orients and assembles, the sources decide, and the click from synthesis to document is where responsibility for the claim transfers to the text built to carry it.
The practical verdict
Begin with iatroX where the problem is broad, clinical and cross-source: initiation, review, uncertainty, conflicting recommendations, the questions that need a corridor found before any room is entered. Open the exact SmPC before acting wherever the decision depends on licensing, dose parameters, formulation, contraindications, interactions or warnings, which is most prescribing decisions at their final step, and treat the current SmPC as authoritative over every summary that pointed to it. Use both for the majority of real questions, in that order, and let the Medicines pages do the join: product navigation with review dates and direct SmPC links, so the path from question to authorised document is two clicks, not a search expedition. The failure modes this division prevents are the two the cluster keeps meeting: treating a synthesis as terminal, the citation-fidelity problem, and treating the SmPC as a pathway guide, the source-purpose problem, and each tool's job is making the other's misuse unnecessary.
Frequently asked questions
If emc is authoritative, why not start there every time?
Because emc is organised by product and clinical questions rarely arrive product-shaped: starting at the source of record works when you already know the exact medicine, brand and formulation, and the front door exists for every question upstream of that point.
Does iatroX cache or restate SmPC content?
The design principle is the source trail: medicines pages identify selected current SmPCs and link out, with review dates shown, and where any summary and the current SmPC could ever diverge, the SmPC governs, which is what source-of-record means.
What about medicines not covered by a summary page?
The routing survives coverage gaps: Ask-iatroX can still orient the question and emc still holds the product record, and a gap in the navigation layer is a convenience cost, never an information dead end.
Should I bookmark emc or rely on links from answers?
Both, deliberately: links from answers serve the question in hand, and a direct emc habit protects you on the days you work without any navigation layer, which is the resilience the source-of-record deserves.
How do PILs fit into this division?
As the patient-facing half of the record: counselling and written information should be checked against the current PIL for the exact product, the same product-level discipline applied to the document patients will actually read.
Does the ten-day update expectation mean emc is always current?
It means the regulatory pipeline is fast once a change is approved, and live MHRA communications remain a separate, faster channel; for high-risk medicines the belt-and-braces habit is the SmPC plus the alerts subscription.